CVS
CVS HEALTH Corp
Consumer Discretionary • CIK 0000064803
Loading...
Market Cap
$132.21B
P/E (TTM)
26.9x
Rev Growth (TTM)
+7.4%
Net Margin (TTM)
1.2%
FCF Yield (TTM)
8.9%
FCF Margin (TTM)
2.8%
Filings
Primary-source SEC disclosures, read end-to-end — every figure traceable to its filing.
10-Q2026 Q22026-08-05source
8-KEarnings2026-08-05source
8-KMay 20262026-05-18source
10-Q2026 Q12026-05-06source
8-KEarnings2026-05-06source
What your agent reads
Company-published material — management’s own words, not SEC-audited. Each source below is labeled so your agent knows what to verify.
Company-published, not SEC-audited
Earnings
Q2
12 days ago
8-K releaseRevenue
$106.10B
+7.3%
Net Income
$3.00B
Flat
EPS
$2.31
+188.8%
Most recent quarterly earnings snapshot
Cash Flow Health
Free Cash Flow7/8 positive
TTM$11.8B
Q2 '26
$5.7B+66%
Q1 '26
$3.4B+30%
FCF Margin
TTM2.8%
Q2 '265.3%+57%
Sector: 2.5%Above Avg
OCF Margin3.6%
OCF/NI3.02x
CapEx Coverage4.9x
FCF Yield8.9%
FCF Growth (2Y)-13%
Cash Conversion Cycle
65 days
DSO: 36+DIO: 29−DPO: –
Cash flow trends & capital efficiency
Capital Allocation
Total Shareholder Yield
TTM2.6%
Div Yield2.6%
Dividend & Payout Metrics
Dividend Yield (TTM)2.6%
FCF Payout Ratio29.2%
Free Cash Flow (TTM)$11.8B
Stock Repurchases ()$0
Capital Return / FCF29.1%
Est. Dividends Paid (TTM)$3.4B
Shows how management rewards shareholders
Valuation Metrics
Price-to-EarningsTTM
26.9x
Volatile
8Q: 9.8x-12960%
High PEG ratio (4.1x) suggests expensive for growth
Valuation Lenses
Earnings
26.9x
vs – sector
Cash Flow
12.9x
EV/FCF vs –
Growth-Adj
4.1xPEG
Expensive for growth
Quality-Adj
5.4P/E per %ROIC
ROIC: 5.0%
Shareholder Returns
Dividend
2.6%
Buyback
–
Total Yield
2.6%
Market Cap$132.21B
EV$179.66B
Multi-angle valuation analysis with sector context
Margins & Efficiency
ROIC 75th pctile
Profitability Cascade
Gross
44.5%
Operating
2.0%
Below Avg in sector
Net
1.2%
Margins Unknown
Return on Invested CapitalTTM
5.0%
Moderate
+0.0% YoY+6.0%
P25MedianP75
75th pctl (med: 0.1%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
1.7%
8Q: 2.1%
Asset Turnover
1.63x
8Q: 1.57x
Leverage (1+D/E)
1.77x
D/E: 0.77x
DuPont: 4.9% ≈ 5.0% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
31.96x
8Q:30.79x
+270.0%
Invested Cap Turn
3.30x
8Q:3.13x
+53.4%
CapEx Intensity
2.4%
8Q:2.2%
CapEx/Depreciation
0.67x
FCF vs Net Margin Gap+1.7 pts
Margin trends, ROIC, and capital efficiency
Balance Sheet & Solvency
D/E 0.77x
Net Debt / EBITDA
–Net Debt: $47.45B
Interest Coverage
–
Leverage Metrics
Debt-to-Equity
0.77x
Balance sheet risk & solvency analysis
Related Research
2 related posts